Progressive Care (RXMD) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue increased 17% year-over-year to $13.5 million, driven by higher prescription and 340B contract revenue.

• Gross profit margin improved to 35% from 31% in the prior year quarter, reflecting better reimbursement rates and higher prescription volumes.

• Net loss for Q2 2024 was $9.3 million, mainly due to $9.8 million in impairment losses for goodwill and intangible assets.

• The company operates two segments: Pharmacy Operations and Third-Party Administration (TPA).

• Positive cash flow from operations was achieved, with a cash balance of $8.5 million as of June 30, 2024.

Financial highlights

• Q2 2024 revenues: $13.5M (Q2 2023: $11.6M); 6M 2024 revenues: $28.1M (6M 2023: $22.9M).

• Prescription revenue, net of PBM fees, rose 11% to $10.5M; 340B contract revenue grew 41% to $3.0M.

• Gross profit for Q2 2024: $4.7M (Q2 2023: $3.6M); gross margin 35% (Q2 2023: 31%).

• Operating expenses for Q2 2024: $14.0M (Q2 2023: $2.9M), including $9.8M in impairment losses.

• Net loss was $9.3M, compared to $4.6M in Q2 2023.

Outlook and guidance

• Management expects current cash position and operating cash flow to support obligations for at least 12 months.

• Merger with NextPlat expected to close in early October 2024, pending shareholder approval, with anticipated cost reductions and expanded services.

• Revenue growth is expected from expanding pharmacy services, new drugs, and additional 340B contracts.